Powering what's possible

in research & development
in partnerships
in your career
in global health
Powering innovation
Protecting health
at Novavax

Novavax Reports CIC and Stand-alone Influenza Phase 3 Trial Results

Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Read press release

U.S. FDA Approves BLA for Nuvaxovid™, Novavax’s COVID-19 Vaccine

Biologics License Application (BLA) approval triggers $175 million Sanofi milestone payment, with additional COVID-19 vaccine milestones and ongoing tiered royalties to be recognized when earned.

Learn more

SHIELD-Utah Study Results

Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Read press release

A Proven Platform

Our proprietary cutting-edge technology platform is revolutionizing the development of vaccines to help prevent some of the world's most challenging diseases.

Combining Novavax’s protein-based nanoparticles with our Matrix-M® adjuvant achieves strong, long-lasting and broad immune responses.1

Learn more

Protein-based Nanoparticles

Our protein-based nanoparticles are made of engineered proteins of the target pathogen used to trigger immune system recognition.2

Learn more

Matrix-M® Adjuvant

Our Matrix-M adjuvant enhances the body's immune response in a targeted and efficient way, significantly improving both the magnitude and the duration of immune response.1

Learn more
Our Pipeline

We are advancing a pipeline of high-value assets targeting areas with unmet medical needs, strong scientific rationale and significant commercial potential.

Learn more

High-Impact Partnerships

Our strategy is to create partnership and collaboration opportunities to maximize the impact and value of our pipeline assets and Matrix-M alone.

Learn more

Latest News

Keep up to date on the latest happenings at Novavax as we tackle the world’s most significant health needs.

Visit the Newsroom

Investors

Learn about and sign up for investor updates, including event notifications, daily stock prices, SEC filings and press releases.

Visit the Investor Hub
  1. Stertman L. et al.; The Matrix-M™ adjuvant: A critical component of vaccines for the 21st century. Hum Vaccin Immunother. 2023 Dec 31;19(1):2189885. doi: 10.1080/21645515.2023.2189885.
  2. Nguyen B. Tolia N; Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines. 2021 May 13;6(1):70. doi: 10.1038/s41541-021-00330-7